Entrectinib for ROS1 ‐rearranged non‐small cell lung cancer after crizotinib‐induced interstitial lung disease: A case report
| العنوان: | Entrectinib for |
|---|---|
| المؤلفون: | Rei Tsutsumi, Takayuki Nakano, Izumi Sato, Yusuke Kunimatsu, Keiko Tanimura, Mai Tanimura, Nobutaka Kataoka, Takayuki Takeda |
| المصدر: | Respirology Case Reports Respirology Case Reports, Vol 9, Iss 11, Pp n/a-n/a (2021) |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | non‐small cell lung cancer, Pulmonary and Respiratory Medicine, entrectinib, medicine.drug_class, Case Report, Entrectinib, Case Reports, drug‐induced interstitial lung disease, Tyrosine-kinase inhibitor, Diseases of the respiratory system, medicine, ROS1, Lung cancer, crizotinib, RC705-779, Oncogene, Crizotinib, business.industry, Interstitial lung disease, medicine.disease, respiratory tract diseases, c‐ros oncogene 1, Cancer research, Prednisolone, business, medicine.drug |
| الوصف: | Chromosomal rearrangements involving the c‐ros oncogene 1 (ROS1) are identified in approximately 1% of non‐small cell lung cancer (NSCLC) patients. Crizotinib is the first tyrosine kinase inhibitor (TKI) against ROS1‐rearranged NSCLC. G2032R, a secondary resistant mutation, is observed in 41% of patients treated with crizotinib. Entrectinib, a TKI against neurotrophic tropomyosin receptor kinase, is reportedly efficacious against ROS1‐rearranged NSCLC. However, ROS1‐G2032R is resistant to entrectinib both in vitro and in vivo. We report an 85‐year‐old female patient with ROS1‐rearranged NSCLC, who developed drug‐induced interstitial lung disease (DI‐ILD) 2 months after crizotinib treatment, and was treated with prednisolone followed by entrectinib. Entrectinib treatment resulted in stable disease with a marginal response after a partial response to crizotinib. Entrectinib treatment following crizotinib cessation due to DI‐ILD was efficacious, which suggested that ROS1‐G2032R gatekeeper mutation, frequently observed in crizotinib‐resistant disease, was absent. We report a patient with c‐ros oncogene 1 (ROS1)‐rearranged non‐small cell lung cancer, who developed drug‐induced interstitial lung disease 2 months after crizotinib treatment, and was sequentially treated with entrectinib, resulting in a stable disease with a marginal response. |
| تدمد: | 2051-3380 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ee2a6e9ac65b23401be11018e0becd5 https://doi.org/10.1002/rcr2.857 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....2ee2a6e9ac65b23401be11018e0becd5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20513380 |
|---|